MedTrace Logo

A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain

NCT07377721 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2026-04-15

No results posted yet for this study

Summary

This study aims to investigate the efficacy and safety of HRS-2129 in Chinese diabetic peripheral neuropathic pain (DPNP) in comparison to placebo.

Conditions

  • Diabetic Peripheral Neuropathic Pain

Interventions

DRUG

HRS-2129 Tablets

HRS-2129 tablets.

DRUG

HRS-2129 Placebo

HRS-2129 placebo.

DRUG

Pregabalin Capsules

Pregabalin capsules.

DRUG

Pregabalin Capsules Placebo

Pregabalin capsules placebo.

Sponsors & Collaborators

  • Shandong Suncadia Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-24
Primary Completion
2026-09-30
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07377721 on ClinicalTrials.gov